Stock report · Delisted · Nasdaq
SpringWorks Therapeutics Inc (SWTX)
46.99USD Delisted Final close · Jun 30, 2025
SWTX no longer trades. SpringWorks Therapeutics was acquired by Merck KGaA on July 1, 2025.
All prices on this page are historical. The last trade was on June 30, 2025, at $46.99.
SWTX stock price history
Final trading statistics
- Final close
- $46.99
- Final trading day
- Jun 30, 2025
- Market cap at delisting
- $3.54B
- Shares outstanding
- 75.35M
- Final 52-week range
- $28.21 – $62.00
- Avg. volume (final 3 mo.)
- 5,792,956
- All-time high
- $93.59 · Feb 2021
- All-time low
- $17.74 · Nov 2019
- Return since IPO
- +107.6%
- Beta
- 0.70
- Book value / share
- $5.57
- Price / book
- 8.44
About SpringWorks Therapeutics Inc
SpringWorks Therapeutics, Inc. was a commercial-stage biopharmaceutical company developing medicines for underserved patients with rare diseases and cancer. It sold OGSIVEO (nirogacestat), an oral gamma secretase inhibitor for desmoid tumors, and GOMEKLI (mirdametinib), an oral MEK1 and MEK2 inhibitor for adults and children two and older with NF1-associated plexiform neurofibromas.
Nirogacestat was also in Phase 2 alone for ovarian granulosa cell tumors, and mirdametinib was in Phase 1/2 for solid tumors with other MAPK changes, including low-grade gliomas in children and young adults. Brimarafenib (BGB-3245), an oral inhibitor of activating BRAF mutations, was also in development.
It licensed nirogacestat and mirdametinib from Pfizer Inc. and TEA Domain inhibitors from Katholieke Universiteit Leuven and the Flanders Institute for Biotechnology. Founded in 2017 and based in Stamford, Connecticut, it was acquired by Merck KGaA on July 1, 2025 for $47.00 in cash per SWTX share; the last trade was on June 30, 2025 at $46.99.
- Exchange (former)
- Nasdaq
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Stamford, CT
- Employees
- 368
- IPO date
- June 5, 1987
- Delisted
- July 1, 2025
- SEC CIK
- 813619
SpringWorks Therapeutics financials before the delisting
The last 5 fiscal years SpringWorks Therapeutics reported as a public company, fiscal year ending December.
SWTX revenue and net income
SWTX earnings per share
SWTX annual financials
| Fiscal year | Revenue | Net income | EPS |
|---|---|---|---|
| FY2024 | $191.59M | −$258.1M | −$3.48 |
| FY2023 | $5.45M | −$325.1M | −$5.15 |
| FY2022 | $6.15M | −$274.2M | −$5.21 |
| FY2021 | $35.00M | −$173.2M | −$3.58 |
| FY2020 | $35.00M | −$44.2M | −$1.05 |
Net income is GAAP. EPS is adjusted (non-GAAP) EPS, as reported.
SpringWorks Therapeutics stock FAQ
What happened to SpringWorks Therapeutics stock?
SpringWorks Therapeutics was acquired by Merck KGaA on July 1, 2025. The final close was $46.99 on June 30, 2025.
What did SpringWorks Therapeutics shareholders receive?
Each SWTX share was converted into $47.00 in cash. The deal was valued at about $3.9 billion.
Can I still buy SWTX stock?
No. SWTX is no longer listed on the Nasdaq or any other U.S. exchange; it was removed on July 1, 2025.
What was the last price of SWTX?
SWTX last closed at $46.99 on June 30, 2025, which valued the company at about $3.54B.
How did SpringWorks Therapeutics do in its last full fiscal year?
In fiscal 2024, its last full year as a public company, SpringWorks Therapeutics reported revenue of $191.59M and net income of −$258.1M.
When did SpringWorks Therapeutics go public?
SpringWorks Therapeutics shares started trading on June 5, 1987.
SWTX no longer trades, so there is no live quote. The information on this page is for reference only and is not investment advice; see our disclaimer.